Search results
Showing 2656 to 2670 of 8914 results
Awaiting development Reference number: GID-TA11945 Expected publication date: TBC
Digital technologies to support self-management of asthma: early value assessment
In development Reference number: GID-HTE10063 Expected publication date: 30 April 2026
Olezarsen for treating familial chylomicronaemia syndrome [ID6585]
In development Reference number: GID-TA11678 Expected publication date: 19 August 2026
Summary of the evidence on infliximab for treating pulmonary sarcoidosis to inform local NHS planning and decision-making
Antimicrobial prescribing: meropenem with vaborbactam (ES21)
Summary of the evidence on antimicrobial prescribing of meropenem with vaborbactam (Vaborem) to inform local NHS planning and decision making
Summary of the evidence on the antimicrobial prescribing of ceftolozane with tazobactam for hospital-acquired pneumonia, including ventilator-associated
Remsima (infliximab biosimilar) for subcutaneous injection for managing rheumatoid arthritis (ES29)
Summary of the evidence on remsima (infliximab biosimilar) for subcutaneous injection for managing rheumatoid arthritis
Antimicrobial prescribing: imipenem with cilastatin and relebactam (ES30)
Summary of the evidence on antimicrobial prescribing: imipenem with cilastatin and relebactam
Summary of the evidence on antimicrobial prescribing: delafloxacin
Summary of the evidence on remsima (infliximab biosimilar) for subcutaneous injection for managing Crohn’s disease and ulcerative colitis
Antimicrobial prescribing: delafloxacin for community-acquired pneumonia (ES37)
Summary of the evidence on delafloxacin for community-acquired pneumonia in adults
Melatonin for treating sleep disorders in adults who are blind (ES38)
Summary of the evidence on melatonin for treating sleep disorders in adults who are blind
Antimicrobial prescribing: oritavancin for acute bacterial skin and skin structure infections (ES39)
Summary of the evidence on oritavancin for acute bacterial skin and skin structure infections (ABSSSI) in adults
Chronic wounds: advanced wound dressings and antimicrobial dressings (ESMPB2)
Summary of the evidence on advanced wound dressings and antimicrobial dressings for managing chronic wounds to inform local NHS planning and decision-making
Early and metastatic HER2-positive breast cancer: subcutaneous trastuzumab (ESNM13)
Summary of the evidence on subcutaneous trastuzumab for HER2-positive breast cancer to inform local NHS planning and decision-making